A routine day
A landscape day, step by step
Search trials, narrow them, read why some stopped, check a product's approvals and patents, export a dated table and see later what changed.
Who it is for A business development or competitive intelligence analyst building a deck.
Step by step
1Pipeline
Search the registered trials
One search by condition, product, sponsor or target.
KRAS G12D Clinical Trials: Selected Registry Landscape
Limit ClinicalTrials.gov only, so trials registered only elsewhere are missing. A target search is a text search.
2Pipeline
Narrow the trials
Filter by phase, status, sponsor class and start year, or press a chart mark.
3Pipeline
Read why trials stopped
Reasons for stopping, grouped by keyword, each with an example as registered.
4Pipeline
Read a product's US approvals and FDA precedent
A product search lists its applications in Drugs@FDA, and the precedent view describes each one.
FDA Complete Response Letters (CRL) and Approval Precedent
Limit Review times and designations cover FDA's new molecular entity and new biologic approvals, April 1985 to December 2025. Other products show fewer facts. It describes past approvals and is not a forecast.
Next, in Patent
5Patent
Check the product's listed patents and exclusivities
The application opens with a range of listed protection, each date traced to its FDA rule and row.
Limit A range of listed dates, not a loss-of-exclusivity date. Litigation, settlements, unlisted patents, at-risk launches, authorised generics and term extensions are not in these files. A missing Paragraph IV row does not mean none was filed.
6Pipeline
Export the deck table and the timeline
One row per trial with its source and dates, and a timeline by phase.
7Pipeline
Reopen the view later
A saved view shows what changed since it was saved: trials added, updated or no longer returned.
What this day does not cover
- Trial counts are not programme counts. Sponsors enter the records, and statuses lag.
- The patent view is at an early stage, with an independent regulatory review pending.
For research and education only, and not medical, investment, regulatory or legal advice.